SCHEMBL6175345

SCHEMBL6175345

N#C[C@@H]1C=CCN1C(=O)C1CCCN1

nearest known ligand 0.57

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 20/20 0.57
DPP8 Q6V1X1 5/20 0.43
DPP9 Q86TI2 4/20 0.43
FAP Q12884 1/20 0.43
DPP7 Q9UHL4 1/20 0.43
ANPEP P15144 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7416194 1.00 DPP4 (0.57) DPP4DPP8DPP9FAPDPP7
SCHEMBL6175339 1.00 DPP4 (0.57) DPP4DPP8DPP9FAPDPP7
SCHEMBL7190126 0.96 DPP4 (0.52) DPP4DPP8DPP9FAPDPP7
SCHEMBL7190130 0.96 DPP4 (0.52) DPP4DPP8DPP9FAPDPP7
SCHEMBL7190829 0.79 DPP4 (0.34) DPP4
SCHEMBL7182927 0.78 SLC6A1 (0.41) DPP4
SCHEMBL7183875 0.77 DPP4 (0.35) DPP4OPRM1OPRD1
SCHEMBL27673378 0.77 DPP4 (0.46) DPP4DPP8DPP9FAPDPP7
SCHEMBL6167910 0.74 DPP4 (0.85) DPP4DPP8DPP9FAPDPP7
SCHEMBL1723021 0.73 DPP4 (1.00) DPP4DPP8DPP9FAPDPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465891-A4 INHIBITORS OF DIPEPTIDYL PEPTIDASE IV GUILFORD PHARM INC (US) 2005-08-17 EP disclosed
US-20050070719-A1 Inhibitors of dipeptidyl peptidase iv GUILFORD PHARMACEUTICALS 2005-03-31 US disclosed
EP-1465891-A2 INHIBITORS OF DIPEPTIDYL PEPTIDASE IV GUILFORD PHARMACEUTICALS INC. (US) 2004-10-13 EP disclosed
US-6645995-B2 Dipeptidyl peptidase-IV (DPP-IV); treating type II diabetes in a human; amino acid amides of 2-cyanopyrrolidine NOVO NORDISK A/S (DK) 2003-11-11 US disclosed
WO-2003057666-A2 INHIBITORS OF DIPEPTIDYL PEPTIDASE IV GUILFORD PHARMACEUTICALS (US) 2003-07-17 WO disclosed
WO-2003057144-A2 CHANGE INHIBITORS OF DIPEPTIDYL PEPTIDASE IV GUILFORD PHARMACEUTICALS (US) 2003-07-17 WO disclosed
US-20020103384-A1 Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV KANSTRUP ANDERS (DK) 2002-08-01 US disclosed
US-6380398-B2 COMPOUNDS SUCH AS (S,S)1-(2-AMINO-3,3-DIMETHYL-BUTYRYL)-2,5-DIHYDRO-1H-PYRROLE-2 -CARBONITRILE ADMINISTERED AS ANTIDIABETIC AGENTS; DIPEPTIDYL PEPTIDASE-IV (DPP-IV) NOVO NORDISK A/S (DK) 2002-04-30 US disclosed
US-20010031780-A1 New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV NOVO NORDISK A/S (DK) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031780-A1 New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV DPP4, DPP7, DPP9 DPP4 1/4885DPP8 5/4885DPP9 3/4885
US-20020103384-A1 Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV DPP4, DPP7, DPP9 DPP4 1/4885DPP8 5/4885DPP9 3/4885
US-20050070719-A1 Inhibitors of dipeptidyl peptidase iv DPP4, DPP3, DPP7 DPP4 1/4885DPP8 5/4885DPP9 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.